Skip to main content

Table 1 Characteristics of 55 patients at study entry

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Female n(%) 38 (69.1)
New onset n(%) 48 (87.3)
Age at onset (years) median (IQR) 4.8 (2.2; 10.0)
Age at MTX start (years) median (IQR) 5.3 (2.8; 10.6)
Interval from onset to MTX start (months) median (IQR) 3.8 (2.5; 6.4)
JIA subtype n
  – Oligoarthritis: persistent/extended 18/3 (32.7 %/5.5 %)
  – Polyarthritis (RF positive n = 1) 25 (45.5 %)
  – Systemic with polyarthritis 5 (9.1 %)
  – Enthesitis-related 3 (5.5 %)
  – Psoriatic 1(1.8 %)
Parent/patient global assessment of well-being mm, median (IQR) 27 (15; 40)
CHAQ 0–3 median (IQR) 0.25 (0.13; 0.69)
ESR mm/h median (IQR) 23 (15; 35)
MTX dose mg/m2 /week median (IQR) 14.2 (12.1;15.2)
  – s.c. (n = 45) 14.4 (13.3; 15.9)
  – p.o. (n = 10) 11.7 (8.3; 12.5)
Concomitant therapy n(%)
  – IATHa 21 (38.2)
  – Sulphasalazine 1 (1.8)
  – Systemic corticosteroids 9 (16.4)
  – Folic acid 5–10 mg/weekb 55 (100)
  1. aWithin 1 month prior to or after MTX start
  2. bOnce weekly dose 24–48 hours post-MTX administration
  3. MTX, Methotrexate
  4. IATH, Intraarticular triamcinolone hexacetonide
  5. CHAQ, Childhood Health Assessment Questionnaire
  6. Global assessments in mm on the 100 mm visual analogue scale